Joshua Reed
2020 - Aldeyra Therapeutics
In 2020, Joshua Reed earned a total compensation of $1.7M as Chief Financial Officer at Aldeyra Therapeutics, a 23% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $152,857 |
|---|---|
| Option Awards | $621,962 |
| Salary | $382,143 |
| Stock Awards | $520,532 |
| Other | $11,400 |
| Total | $1,688,894 |
Reed received $622K in option awards, accounting for 37% of the total pay in 2020.
Reed also received $152.9K in non-equity incentive plan, $382.1K in salary, $520.5K in stock awards and $11.4K in other compensation.
Rankings
In 2020, Joshua Reed's compensation ranked 6,314th out of 13,090 executives tracked by ExecPay. In other words, Reed earned more than 51.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,314 out of 13,090 | 52nd |
Division Manufacturing | 2,602 out of 5,618 | 54th |
Major group Chemicals And Allied Products | 1,048 out of 2,251 | 53rd |
Industry group Drugs | 905 out of 1,951 | 54th |
Industry Pharmaceutical Preparations | 676 out of 1,456 | 54th |
Source: SEC filing on April 25, 2022.
Reed's colleagues
We found one more compensation record of an executive who worked with Joshua Reed at Aldeyra Therapeutics in 2020.
2020
Todd Brady
Aldeyra Therapeutics